Civco acquires maker of positioning devices
Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The
Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The subsidiary of Colorado MedTech made the purchase with 127,000 shares of MedTech stock and $2 million in cash at closing. An additional $2.2 million will be paid if certain performance standards are met. Annualized revenues associated with the acquisition are expected to be about $2 million. Barzell-Whitmore's devices are used in evaluation of colorectal disease and the treatment of prostate cancer. Expected future applications will involve laparoscopic surgery and the treatment of benign prostate hyperplasia. The acquisition will expand the portfolio of Civco products used to perform image-guided procedures.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 2nd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 2nd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 2nd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
